JP2019535311A - 合成キメラポックスウイルス - Google Patents

合成キメラポックスウイルス Download PDF

Info

Publication number
JP2019535311A
JP2019535311A JP2019545700A JP2019545700A JP2019535311A JP 2019535311 A JP2019535311 A JP 2019535311A JP 2019545700 A JP2019545700 A JP 2019545700A JP 2019545700 A JP2019545700 A JP 2019545700A JP 2019535311 A JP2019535311 A JP 2019535311A
Authority
JP
Japan
Prior art keywords
virus
schpxv
dna
scopv
genome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019545700A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535311A5 (enExample
Inventor
デイビッド エバンス，
デイビッド エバンス，
ライアン ノイス，
ライアン ノイス，
セス レーダーマン，
セス レーダーマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2019535311A publication Critical patent/JP2019535311A/ja
Publication of JP2019535311A5 publication Critical patent/JP2019535311A5/ja
Priority to JP2022140113A priority Critical patent/JP2022164900A/ja
Priority to JP2024093677A priority patent/JP2024107257A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019545700A 2016-11-02 2017-11-02 合成キメラポックスウイルス Pending JP2019535311A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022140113A JP2022164900A (ja) 2016-11-02 2022-09-02 合成キメラポックスウイルス
JP2024093677A JP2024107257A (ja) 2016-11-02 2024-06-10 合成キメラポックスウイルス

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662416577P 2016-11-02 2016-11-02
US62/416,577 2016-11-02
US201662434794P 2016-12-15 2016-12-15
US62/434,794 2016-12-15
PCT/US2017/059782 WO2018085582A1 (en) 2016-11-02 2017-11-02 Synthetic chimeric poxviruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022140113A Division JP2022164900A (ja) 2016-11-02 2022-09-02 合成キメラポックスウイルス

Publications (2)

Publication Number Publication Date
JP2019535311A true JP2019535311A (ja) 2019-12-12
JP2019535311A5 JP2019535311A5 (enExample) 2020-12-10

Family

ID=62075555

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019545700A Pending JP2019535311A (ja) 2016-11-02 2017-11-02 合成キメラポックスウイルス
JP2022140113A Withdrawn JP2022164900A (ja) 2016-11-02 2022-09-02 合成キメラポックスウイルス
JP2024093677A Pending JP2024107257A (ja) 2016-11-02 2024-06-10 合成キメラポックスウイルス

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022140113A Withdrawn JP2022164900A (ja) 2016-11-02 2022-09-02 合成キメラポックスウイルス
JP2024093677A Pending JP2024107257A (ja) 2016-11-02 2024-06-10 合成キメラポックスウイルス

Country Status (14)

Country Link
US (2) US11345896B2 (enExample)
EP (1) EP3535389A4 (enExample)
JP (3) JP2019535311A (enExample)
CN (1) CN110431228B (enExample)
AU (2) AU2017353868C1 (enExample)
BR (1) BR112019008781A2 (enExample)
CA (1) CA3042694A1 (enExample)
IL (2) IL319942A (enExample)
MX (1) MX2019005102A (enExample)
NZ (1) NZ752893A (enExample)
SG (1) SG11201903893PA (enExample)
TW (2) TW202528334A (enExample)
WO (1) WO2018085582A1 (enExample)
ZA (3) ZA201902868B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522784A (ja) * 2018-05-02 2021-09-02 トニックス ファーマ ホールディングス リミテッド 合成キメラワクシニアウイルス
JP2023515582A (ja) * 2020-02-26 2023-04-13 トニックス ファーマ リミテッド ＳＡＲＳ－ＣｏＶ－２ウイルスに対する、組換えポックスウイルスに基づくワクチン

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017353868C1 (en) 2016-11-02 2024-06-06 Tonix Pharma Limited Synthetic chimeric poxviruses
US20180228921A1 (en) * 2017-02-13 2018-08-16 Excision Biotherapeutics, Inc. Visualizing viral reservoirs and dissemination in vivo
WO2020153734A1 (ko) * 2019-01-25 2020-07-30 바이로큐어 주식회사 다람쥐 섬유종 바이러스 및 리오바이러스를 포함하는 암 예방 또는 치료용 약학적 조성물
US20230097513A1 (en) * 2020-02-03 2023-03-30 City Of Hope Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
JP2024505274A (ja) 2021-02-02 2024-02-05 ゲオバックス インコーポレイテッド ワクチン接種中のｔ細胞プライミングの強化において使用されるウイルスコンストラクト
WO2023168286A1 (en) 2022-03-01 2023-09-07 Tonix Pharmaceuticals Holding Corp. Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof
CN117264909B (zh) * 2023-10-25 2024-11-26 深圳湾实验室 反式互补缺陷猴痘病毒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014034A1 (en) * 2002-06-06 2004-01-22 Evans David H Method of producing a recombinant virus

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2787577A (en) 1953-12-01 1957-04-02 Lilly Co Eli Stable smallpox vaccine
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6723325B1 (en) 2001-04-23 2004-04-20 Acambis, Inc. Smallpox vaccine
US20070275010A1 (en) 2003-09-18 2007-11-29 Mark Feinberg Mva Vaccines
WO2006022215A1 (ja) 2004-08-23 2006-03-02 The Japan Health Sciences Foundation SARS-コロナウイルスタンパク質をコードするDNAを保有する組換えワクチニアウイルスDIs株、およびその利用
CN101020055B (zh) 2006-02-16 2012-08-08 中国疾病预防控制中心性病艾滋病预防控制中心 基于复制型痘苗病毒载体的sars疫苗
US20090098529A1 (en) 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
WO2009117030A2 (en) * 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
FI20115914L (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
WO2014160475A1 (en) 2013-03-13 2014-10-02 Aboody Karen S Tropic cell based virotherapy for the treatment of cancer
ES2768292T3 (es) 2013-04-10 2020-06-22 Tot Shanghai R&D Center Co Ltd Cepas de virus vaccinia mutante, usos de estas y método para producirlas
EP3045181B1 (en) 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
CN115212301A (zh) 2015-08-11 2022-10-21 卡利迪生物治疗有限公司 用以癌症治疗的天花疫苗
EP3515419A4 (en) 2016-09-21 2020-06-10 Stephen H. Thorne High mobility group box i mutant
AU2017353868C1 (en) 2016-11-02 2024-06-06 Tonix Pharma Limited Synthetic chimeric poxviruses
ES2702618B2 (es) 2017-09-04 2019-10-31 Inst De Salud Carlos Iii Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica.
MX2020011586A (es) 2018-05-02 2020-12-07 David Evans Virus vaccinia quimerico sintetico.
EP3787681A4 (en) 2018-05-02 2022-01-19 Tonix Pharma Holdings Limited Stem cells comprising synthetic chimeric vaccinia virus and methods of using them

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014034A1 (en) * 2002-06-06 2004-01-22 Evans David H Method of producing a recombinant virus

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522784A (ja) * 2018-05-02 2021-09-02 トニックス ファーマ ホールディングス リミテッド 合成キメラワクシニアウイルス
JP2023515582A (ja) * 2020-02-26 2023-04-13 トニックス ファーマ リミテッド ＳＡＲＳ－ＣｏＶ－２ウイルスに対する、組換えポックスウイルスに基づくワクチン

Also Published As

Publication number Publication date
IL266399B1 (en) 2025-05-01
AU2017353868A1 (en) 2019-05-16
AU2017353868B2 (en) 2024-02-29
IL266399A (en) 2019-06-30
ZA202204981B (en) 2024-09-25
ZA202403393B (en) 2025-08-27
TWI887191B (zh) 2025-06-21
US20180251736A1 (en) 2018-09-06
ZA201902868B (en) 2022-12-21
JP2022164900A (ja) 2022-10-27
CA3042694A1 (en) 2018-05-11
IL266399B2 (en) 2025-09-01
TW202528334A (zh) 2025-07-16
IL319942A (en) 2025-05-01
AU2017353868C1 (en) 2024-06-06
AU2024200997A1 (en) 2024-03-07
TW201819400A (zh) 2018-06-01
US12365879B2 (en) 2025-07-22
EP3535389A4 (en) 2020-06-03
JP2024107257A (ja) 2024-08-08
CN110431228B (zh) 2024-04-02
MX2019005102A (es) 2019-10-30
SG11201903893PA (en) 2019-05-30
EP3535389A1 (en) 2019-09-11
US11345896B2 (en) 2022-05-31
WO2018085582A1 (en) 2018-05-11
BR112019008781A2 (pt) 2019-07-16
NZ752893A (en) 2025-10-31
US20230002741A1 (en) 2023-01-05
CN110431228A (zh) 2019-11-08

Similar Documents

Publication Publication Date Title
US12365879B2 (en) Synthetic chimeric poxviruses
JP2025178289A (ja) 合成キメラワクシニアウイルス
WO2021174142A1 (en) Recombinant poxvirus based vaccine against sars-cov-2 virus
EP3158060B1 (en) Method for rapid generation of an infectious rna virus
US20210236619A1 (en) Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
Deng et al. Genomic characteristics of an avipoxvirus 282E4 strain
HK40014109B (zh) 合成嵌合痘病毒
HK40014109A (en) Synthetic chimeric poxviruses
WO2023168286A1 (en) Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof
Ishihara et al. Removal of Inserted BAC after linearizatiON (RIBON)—a novel strategy to excise the mini-F sequences from viral BAC vectors
Holley Mechanistic Constraints on the Formation of Virion Morphotypes in Vaccinia Virus
Ríos et al. INVESTIGATION OF POXVIRUS HOST-RANGE AND GENE EXPRESSION IN MAMMALIAN CELLS.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201027

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230412

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230412

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230420

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230523

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251010